South Africa Recalls Contraceptive Pills Due to Packaging Error

South African regulators have ordered the recall of a specific batch of the widely used Yaz Plus contraceptive pill due to a packaging error that could render the contraception ineffective. Bayer Ltd, the manufacturer, advised women who have used pills from the compromised batch to cease use at once and consult a medical professional. The packaging error resulted in several blister packs containing 24 inactive pills rather than 24 active, hormone-containing pills. This problem impacted only a restricted quantity of packets within batch WEW96J, which has an expiration date of March 2026. Bayer initiated the recall of the faulty batch, collaborating with the South Africa Health Products Regulatory Agency. The company emphasized that the “root cause” of the packaging error has been pinpointed and addressed. Typically, a Yaz Plus contraceptive pack includes 24 active, hormone-containing pills, which are pink, followed by four light orange, hormone-free inactive pills. However, in the recalled batch, several packs contained 24 hormone-free inactive pills and merely four active hormone pills. This raises concerns that individuals might face an elevated risk of pregnancy if they consumed inactive pills under the impression they were using effective hormonal contraception. Bayer Ltd’s official recall notice stated: “While only a limited number of packs from the respective batch is affected, as a precautionary measure, no tablets from these packs shall be used until you have consulted your healthcare practitioner, as they may potentially not provide the contraceptive protection you expect.” Individuals who have purchased a packet of pills from the specified batch are advised to return them to pharmacies to receive either a replacement or a refund. Healthcare professionals, including those in hospitals, pharmacies, doctors, nurses, and wholesalers holding packets from the impacted batch, are also instructed to return them. In a formal statement, Bayer Ltd confirmed that “the root cause for the mix-up of tablets in the packaging has been identified and corrective measures have been implemented”. The company clarified that this incident is confined to a single batch, with no other batches being affected. A helpline has been established by the company to address any additional inquiries.